ArticleProbiotics and antimicrobial proteins2026
Lacticaseibacillus Casei KGC1201 Isolated from Panax Ginseng Mitigates Dextran Sulfate Sodium-Induced Colitis by Modulating the Gut Environment.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotypic, Genomic, and In Vivo Characterization of a Host-Derived Limosilactobacillus fermentum RLF77 with Potential to Prevent Post-weaning Diarrhea in Rabbits.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Gut microbiota dysbiosis is closely linked to the pathogenesis of inflammatory bowel disease (IBD), highlighting the therapeutic potential of probiotics that affect the gut microbiome when ingested. In this study, we evaluated the effects of Lacticaseibacillus casei KGC1201, a strain isolated from Panax ginseng, on a mouse model of dextran sulfate sodium (DSS)-induced colitis. L. casei KGC1201 culture powder at doses of 206 and 412 mg/kg was administered orally once daily, one week before DSS administration until sacrifice. A 2% DSS solution was provided ad libitum in drinking water for 7 days, and the mice were sacrificed 3 days after DSS withdrawal. Body weight changes, stool condition, colon length, and the histopathology of the colon tissue were assessed. Additionally, fecal samples were analyzed by 16 S rRNA sequencing to evaluate the gut microbiota composition. Administration of L. casei KGC1201 alleviated colitis symptoms such as weight loss, diarrhea, and decreased colon length. It also modulated the gut microbiota composition and beneficial functional metabolic pathways, including promoting the growth of beneficial gut microbiota. Moreover, it promoted intestinal epithelial regeneration by activating Wnt3a/β-catenin signaling, a crucial pathway for epithelial self-renewal and repair. These findings suggest that the ginseng-derived L. casei KGC1201 is a promising probiotic candidate for mitigating colitis and supporting intestinal health in patients with IBD.
Indexed as
Identifiers
41317253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.